The next generation virus-like particle platform for the treatment of peanut allergy.

Sobczak, Jan M; Krenger, Pascal S; Storni, Federico; Mohsen, Mona O; Balke, Ina; Reseviča, Gunta; Heath, Matthew D; Carreno Velazquez, Thalia L; Kramer, Matthias F; Scott, Callum J W; Skinner, Murray A; Zeltiņš, Andris; Kündig, Thomas M; Vogel, Monique; Bachmann, Martin F (2023). The next generation virus-like particle platform for the treatment of peanut allergy. Allergy, 78(7), pp. 1980-1996. Wiley-Blackwell 10.1111/all.15704

[img] Text
Allergy_-_2023_-_Sobczak_-_The_next_generation_virus_like_particle_platform_for_the_treatment_of_peanut_allergy.pdf - Accepted Version
Restricted to registered users only until 8 March 2024.
Available under License Publisher holds Copyright.

Download (12MB) | Request a copy

BACKGROUND

Allergy to peanut is one of the leading causes of anaphylactic reactions among food allergic patients. Immunization against peanut allergy with a safe and protective vaccine holds a promise to induce durable protection against anaphylaxis caused by exposure to peanut. A novel vaccine candidate (VLP Peanut), based on virus-like particles (VLPs), is described here for the treatment of peanut allergy.

METHODS AND RESULTS

VLP Peanut consist of two proteins: a capsid subunit derived from Cucumber mosaic virus engineered with a universal T cell epitope (CuMVTT ) and a CuMVTT subunit fused with peanut allergen Ara h 2 (CuMVTT -Ara h 2), forming mosaic VLPs. Immunizations with VLP Peanut in both naïve and peanut-sensitised mice resulted in a significant anti-Ara h 2 IgG response. Local and systemic protection induced by VLP Peanut were established in mouse models for peanut allergy following prophylactic, therapeutic and passive immunizations. Inhibition of FcγRIIb function resulted in a loss of protection, confirming the crucial role of the receptor in conferring cross protection against peanut allergens other than Ara h 2.

CONCLUSION

VLP Peanut can be delivered to peanut-sensitized mice without triggering allergic reactions, whilst remaining highly immunogenic and offering protection against all peanut allergens. In addition, vaccination ablates allergic symptoms upon allergen challenge. Moreover, the prophylactic immunization setting conferred the protection against subsequent peanut-induced anaphylaxis, showing the potential for preventive vaccination. This highlights the effectiveness of VLP Peanut as a prospective break-through immunotherapy vaccine candidate towards peanut allergy. VLP Peanut has now entered clinical development with the study PROTECT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Rheumatologie

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute for Immunology [discontinued]
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine

UniBE Contributor:

Sobczak, Jan Mateusz, Krenger, Pascal Siegfried, Storni, Federico Lorenzo, Mohsen, Mona Omar Mahmoud, Vogel, Monique, Bachmann, Martin (B)

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0105-4538

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Pubmed Import

Date Deposited:

09 Mar 2023 10:45

Last Modified:

01 Jul 2023 00:13

Publisher DOI:

10.1111/all.15704

PubMed ID:

36883475

Uncontrolled Keywords:

Peanut allergy novel therapy vaccine virus-like particles

BORIS DOI:

10.48350/179750

URI:

https://boris.unibe.ch/id/eprint/179750

Actions (login required)

Edit item Edit item
Provide Feedback